Tampe, Björn

[["dc.bibliographiccitation.artnumber","e0284"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Critical Care Explorations"],["dc.bibliographiccitation.lastpage","5"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Hofmann-Winkler, Heike"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Alt-Epping, Sabine"],["dc.contributor.author","Bräuer, Anselm"],["dc.contributor.author","Büttner, Benedikt"],["dc.contributor.author","Müller, Martin"],["dc.contributor.author","Fricke, Torben"],["dc.contributor.author","Grundmann, Julian"],["dc.contributor.author","Harnisch, Lars-Olav"],["dc.contributor.author","Heise, Daniel"],["dc.contributor.author","Kernchen, Andrea"],["dc.contributor.author","Pressler, Meike"],["dc.contributor.author","Stephani, Caspar"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Kaul, Artur"],["dc.contributor.author","Gärtner, Sabine"],["dc.contributor.author","Kramer, Stefanie"],["dc.contributor.author","Pöhlmann, Stefan"],["dc.contributor.author","Winkler, Martin Sebastian"],["dc.date.accessioned","2020-11-27T11:23:20Z"],["dc.date.accessioned","2021-10-27T13:22:21Z"],["dc.date.available","2020-11-27T11:23:20Z"],["dc.date.available","2021-10-27T13:22:21Z"],["dc.date.issued","2020"],["dc.description.abstract","Objectives: Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown. Design: Retrospective observational case series. Setting: Patient treated in ICU of University hospital Göttingen, Germany. Patients: Eleven critical ill coronavirus disease 2019 patients with organ failure were treated in ICU. Interventions: Compassionate use of camostat mesylate (six patients, camostat group) or hydroxychloroquine (five patients, hydroxychloroquine group). Measurements and Main Results: Clinical courses were assessed by Sepsis-related Organ Failure Assessment score at days 1, 3, and 8. Further, viral load, oxygenation, and inflammatory markers were determined. Sepsis-related Organ Failure Assessment score was comparable between camostat and hydroxychloroquine groups upon ICU admission. During observation, the Sepsis-related Organ Failure Assessment score decreased in the camostat group but remained elevated in the hydroxychloroquine group. The decline in disease severity in camostat mesylate treated patients was paralleled by a decline in inflammatory markers and improvement of oxygenation. Conclusions: The severity of coronavirus disease 2019 decreased upon camostat mesylate treatment within a period of 8 days and a similar effect was not observed in patients receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within randomized clinical trials."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2020"],["dc.identifier.doi","10.1097/CCE.0000000000000284"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17663"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92088"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","2639-8028"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1407"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Missbach-Guentner, Jeannine"],["dc.contributor.author","Pinkert-Leetsch, Diana"],["dc.contributor.author","Dullin, Christian"],["dc.contributor.author","Ufartes, Roser"],["dc.contributor.author","Hornung, Daniel"],["dc.contributor.author","Tampe, Bjoern"],["dc.contributor.author","Zeisberg, Michael"],["dc.contributor.author","Alves, Frauke"],["dc.date.accessioned","2019-07-09T11:45:05Z"],["dc.date.available","2019-07-09T11:45:05Z"],["dc.date.issued","2018"],["dc.description.abstract","The increasing number of patients with end stage chronic kidney disease not only calls for novel therapeutics but also for pioneering research using convincing preclinical disease models and innovative analytical techniques. The aim of this study was to introduce a virtual histology approach using micro computed tomography (µCT) for the entire murine kidney in order to close the gap between single slice planar histology and a 3D high resolution dataset. An ex vivo staining protocol based on phosphotungstic acid diffusion was adapted to enhance renal soft tissue x-ray attenuation. Subsequent CT scans allowed (i) the detection of the renal cortex, medulla and pelvis in greater detail, (ii) the analysis of morphological alterations, (iii) the quantification of the volume as well as the radio-opacity of these portions and (iv) the quantification of renal fibrotic remodeling based on altered radio-opacity using the unilateral ureteral obstruction model. Thus, virtual histology based on PTA contrast enhanced CT will in future help to refine the outcome of preclinical research on kidney associated murine disease models."],["dc.identifier.doi","10.1038/s41598-018-19773-5"],["dc.identifier.pmid","29362427"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59157"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","3D virtual histology of murine kidneys -high resolution visualization of pathological alterations by micro computed tomography."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0199345"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.lastpage","e0199345"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Wienbeck, Susanne"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Patschan, Daniel"],["dc.contributor.author","Zeisberg, Michael"],["dc.contributor.author","Vasko, Radovan"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Müller, Gerhard A."],["dc.date.accessioned","2019-07-09T11:45:40Z"],["dc.date.available","2019-07-09T11:45:40Z"],["dc.date.issued","2018"],["dc.description.abstract","RATIONALE: Central venous catheter (CVC) placement is a standard procedure in critical care. Ultrasound guidance during placement is recommended by current guidelines, but there is no consensus on the best method for evaluating the correct CVC tip position. Recently, the \"rapid atrial swirl sign\" (RASS) has been investigated in a limited number of studies. OBJECTIVES: We performed a prospective diagnostic accuracy study of focused echocardiography for the evaluation of CVC tip position in our medical ICU and IMC units. METHODS: We performed a prospective diagnostic accuracy study in 100 patients admitted to the Intensive Care Unit and Intermediate Care Unit at our center. The first 10 subjects were assessed by one staff physician investigator (reference cohort), the remaining 90 patients by different residents (test cohort). All patients received a post-procedural chest radiograph (CXR) as gold standard. CVC placement was assessed with focused echocardiography performed by residents after a short training session. A rapid opacification of the right atrium (RASS) after injection of 10 mL of normal saline was regarded as \"positive\", flush after more than two seconds was defined as \"delayed\", no flush was a \"negative\" test result. MEASUREMENTS AND MAIN RESULTS: Overall sensitivity of the RASS was 100% (95% CI 73.54-100%), specificity was 94.32% (CI 87.24-98.13%). Positive and negative predictive values were 70.59% (CI 44.04-89.09%) and 100% (CI 95.65-100%), respectively. Median time for echocardiographic testing was 5 minutes (1-28) in the whole cohort, CXRs were available after 49.5 minutes (13-254). Interrater agreement of the RASS was 0.77 (Cohen's kappa), Measurement of CVC tip position was not different between two observers. Test characteristics were similar among differently experienced residents. CONCLUSIONS: Presence of the RASS by focused echocardiography showed excellent sensitivity and specificity and was equally performed by residents after minimal training. In patients with a positive RASS, routine CXR can be safely omitted, reducing time, costs and radiation exposure. A negative RASS should lead to a search for misplaced catheters. CLINICAL TRIAL REGISTRATION: The study was registered with www.clinicaltrials.gov (NCT02661607)."],["dc.identifier.doi","10.1371/journal.pone.0199345"],["dc.identifier.pmid","30011285"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15276"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59280"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","The \"rapid atrial swirl sign\" for assessing central venous catheters: Performance by medical residents after limited training."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0206786"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","PLOS ONE"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Životić, Maja"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Müller, Gerhard"],["dc.contributor.author","Müller, Claudia"],["dc.contributor.author","Lipkovski, Aleksandar"],["dc.contributor.author","Xu, Xingbo"],["dc.contributor.author","Nyamsuren, Gunsmaa"],["dc.contributor.author","Zeisberg, Michael"],["dc.contributor.author","Marković-Lipkovski, Jasmina"],["dc.date.accessioned","2019-07-09T11:50:17Z"],["dc.date.available","2019-07-09T11:50:17Z"],["dc.date.issued","2018"],["dc.description.abstract","Neural cell adhesion molecule (NCAM) and fibroblast growth factor receptor 1 (FGFR1) cross-talk have been involved in epithelial-to-mesenchymal transition (EMT) process during carcinogenesis. Since EMT also contributes to maladaptive repair and parenchymal damage during renal fibrosis, we became encouraged to explore the role of NCAM/FGFR1 signaling as initiating or driving forces of EMT program in cultured human proximal tubular epithelial cells (TECs). TECs stimulated with TGF-β1 (10ng/mL) was used as an established in vitro EMT model. TGF-β1 downstream effectors were detected in vitro, as well as in 50 biopsies of different human kidney diseases to explore their in vivo correlation. NCAM/FGFR1 signaling and its modulation by FGFR1 inhibitor PD173074 (100nM) were analyzed by light microscopy, immunolabeling, qRT-PCR and scratch assays. Morphological changes associated with EMT appeared 48h after TGF-ß1 treatment and was clearly apparent after 72 hours, followed by loss of CDH1 (encoding E-Cadherin) and transcriptional induction of SNAI1 (SNAIL), SNAI2 (SLUG), TWIST1, MMP2, MMP9, CDH2 (N-Cadherin), ITGA5 (integrin-α5), ITGB1 (integrin-β1), ACTA2 (α-SMA) and S100A4 (FSP1). Moreover, at the early stage of EMT program (24 hours upon TGF-β1 exposure), transcriptional induction of several NCAM isoforms along with FGFR1 was observed, implicating a mechanistic link between NCAM/FGFR1 signaling and induction of EMT. These assumptions were further supported by the inhibition of the EMT program after specific blocking of FGFR1 signaling by PD173074. Finally, there was evidence for an in vivo TGF-β1 pathway activation in diseased human kidneys and correlation with impaired renal excretory functions. Collectively, NCAM/FGFR1 signaling appears to be involved in the initial phase of TGF-ß1 initiated EMT which can be effectively suppressed by application of FGFR inhibitor."],["dc.identifier.doi","10.1371/journal.pone.0206786"],["dc.identifier.pmid","30383875"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15900"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59738"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Modulation of NCAM/FGFR1 signaling suppresses EMT program in human proximal tubular epithelial cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","224"],["dc.bibliographiccitation.journal","Frontiers in Medicine"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Herath, Judith"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Korsten, Peter"],["dc.date.accessioned","2019-07-09T11:45:44Z"],["dc.date.available","2019-07-09T11:45:44Z"],["dc.date.issued","2018"],["dc.description.abstract","Background: Valproic acid (VPA) has been approved for the treatment of seizure disorders. It is also commonly used in psychiatric disorders, such as schizophrenia spectrum disorders. With increasing administration, reports of intoxications are more frequently reported. The most common findings of VPA intoxication are central nervous system depression, respiratory depression, hypotension, metabolic acidosis, and elevated lactate, among others. Methods: We describe a case report of VPA intoxication with hemodiafiltration (HDF) as extracorporeal treatment (ECTR) for removal of VPA. This treatment modality has only rarely been reported in the current literature. In addition, we performed an updated systematic literature review (SLR) of additional cases on the topic ranging fromDecember 1st, 2014 to April 20th, 2018. We searched MEDLINE and Web of Science for relevant references. Results: In the presented case, VPA intoxication occurred in a 46-year-old female patient after oral ingestion of 56 g of VPA. In addition to vasopressors and endotracheal intubation, we administered L-Carnitine (L-Car) and performed hemodiafiltration treatment. After intravenous therapy with L-Car and simultaneous HDF sessions, we observed full recovery without neurological sequelae. The SLR identified 8 additional articles reporting favorable outcomes with extracorporeal treatments in most cases. Conclusion: HDF and other extracorporeal procedures are safe and effective therapeutic options in patients with VPA intoxication. The choice of ECTR modalitymainly depends on local experience and the setting. In the present case, ingestion of 56 g was successfully treated with HDF. These findings are in line with several other case reports describing positive outcomes. Extracorporeal treatment, including HDF, should be considered early in the management of VPA intoxication. Supporting evidence is emerging, but it is of limited quality."],["dc.identifier.doi","10.3389/fmed.2018.00224"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15284"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59300"],["dc.language.iso","en"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/15300 but duplicate"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","2296-858X"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.subject.ddc","610"],["dc.title","Hemodiafiltration Treatment for Severe Valproic Acid Intoxication: Case Report and Updated Systematic Literature Review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]